D. E. Shaw & Co. Inc. Has $2.43 Million Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

D. E. Shaw & Co. Inc. lessened its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 47.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 184,117 shares of the company’s stock after selling 168,241 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in Syndax Pharmaceuticals were worth $2,434,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of SNDX. R Squared Ltd bought a new stake in shares of Syndax Pharmaceuticals during the 4th quarter valued at approximately $26,000. Virtus ETF Advisers LLC boosted its position in Syndax Pharmaceuticals by 18.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company’s stock valued at $70,000 after buying an additional 827 shares in the last quarter. Cape Investment Advisory Inc. grew its stake in shares of Syndax Pharmaceuticals by 157.1% during the fourth quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company’s stock worth $85,000 after buying an additional 3,927 shares during the last quarter. KBC Group NV increased its holdings in shares of Syndax Pharmaceuticals by 104.8% during the fourth quarter. KBC Group NV now owns 6,954 shares of the company’s stock worth $92,000 after buying an additional 3,559 shares in the last quarter. Finally, Optimize Financial Inc acquired a new position in shares of Syndax Pharmaceuticals during the fourth quarter worth $152,000.

Analysts Set New Price Targets

SNDX has been the subject of several research reports. HC Wainwright reiterated a “buy” rating and issued a $51.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, March 4th. Citigroup cut their target price on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th. JPMorgan Chase & Co. upped their price target on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an “overweight” rating in a research report on Thursday, March 20th. Guggenheim reaffirmed a “buy” rating and set a $32.00 price target on shares of Syndax Pharmaceuticals in a research note on Tuesday, May 6th. Finally, Scotiabank boosted their price objective on shares of Syndax Pharmaceuticals from $16.00 to $17.00 and gave the stock a “sector perform” rating in a research note on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $35.91.

Syndax Pharmaceuticals Price Performance

SNDX stock opened at $10.57 on Wednesday. The firm has a 50 day simple moving average of $11.97 and a two-hundred day simple moving average of $13.94. The stock has a market cap of $909.52 million, a PE ratio of -2.91 and a beta of 0.82. Syndax Pharmaceuticals, Inc. has a one year low of $8.58 and a one year high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its earnings results on Monday, May 5th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.04) by $0.06. The business had revenue of $20.04 million for the quarter, compared to the consensus estimate of $15.88 million. During the same period in the prior year, the business posted ($0.85) EPS. Syndax Pharmaceuticals’s revenue for the quarter was up 1900.0% on a year-over-year basis. On average, research analysts expect that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current fiscal year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).